We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Urine-Based Test Detects Prostate Cancers

By LabMedica International staff writers
Posted on 04 Sep 2025

Prostate cancer is one of the leading causes of death in men in the US and is usually detected through prostate-specific antigen (PSA) blood tests. More...

However, PSA is not very specific, meaning many men undergo invasive biopsies that are often negative and carry risks. In addition, PSA testing can lead to overtreatment of low-grade cancers. Now, researchers have identified biomarkers in urine that can accurately detect prostate cancer and reduce unnecessary procedures.

A team at Johns Hopkins Medicine (Baltimore, MD, USA) working with several partner institutions has developed a urine-based test using three biomarkers: TTC3, H4C5, and EPCAM. These markers were present in patients with prostate cancer but nearly absent after prostate-removal surgery, confirming their origin in prostate tissue. The test analyzes RNA extracted from prostate cells shed in urine using RNA sequencing, qPCR, and immunohistochemistry to validate expression patterns.

In development and validation studies using over 1,300 urine specimens, the test achieved an area under the curve (AUC) of 0.92, correctly identifying prostate cancer 91% of the time and ruling out non-cancer cases 84% of the time. The results, published in eBioMedicine, show that it also distinguished prostate cancer from benign conditions such as BPH and prostatitis, outperforming PCA3.

The test showed strong diagnostic accuracy even in PSA-negative patients, maintaining performance of 78.6% and 85.7% across cohorts. By distinguishing cancer from benign conditions and detecting cases with normal PSA levels, it could complement or even surpass PSA screening. Researchers plan to further develop the assay for clinical use, explore its integration with PSA as a “super PSA,” and test it independently at other institutions before broader deployment.

“This new biomarker panel offers a promising, sensitive and specific, noninvasive diagnostic test for prostate cancer,” said Ranjan Perera, Ph.D., senior study author. “It has the potential to accurately detect prostate cancer, reduce unnecessary biopsies, improve diagnostic accuracy in PSA-negative patients, and serve as the foundation for both laboratory-developed and in vitro diagnostic assays.”

Related Links:
Johns Hopkins Medicine


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Portable Electronic Pipette
Mini 96
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
New
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.